Credence Research has published a new research report titled “Androgens and Anabolic Steroids Market By Indication (Hypogonadism, Anaemia, Breast Cancer, Others); By Drugs (Testosterone, Methyltestosterone, Oxymetholone, Others); By Type (Prescription Drugs, Over-the-counter (OTC) Drugs); By Route of Administration (Oral, Parenteral, Others); By End-Users (Hospitals, Specialty Clinics, Homecare, Others); By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032” The Androgens and Anabolic Steroids Market is projected to grow from USD 78,584.68 million in 2025 to an estimated USD 158,479.9 million by 2032, registering a CAGR of 10.5% during the forecast period. Market expansion reflects rising clinical diagnosis of testosterone deficiency, increasing awareness of age-related hormone decline, and broader access to structured endocrinology services across developed and emerging healthcare systems.
The Androgens and Anabolic Steroids Market continues to evolve within a tightly regulated therapeutic framework. Physicians increasingly rely on evidence-based clinical guidelines to diagnose and manage hypogonadism and hormone-related conditions, strengthening safe prescription practices. Advanced drug delivery systems, including long-acting injectables, oral testosterone formulations, and transdermal therapies, improve patient adherence and expand therapeutic flexibility. At the same time, digital health platforms and structured follow-up protocols enhance monitoring and treatment continuity. While regulatory scrutiny and safety concerns remain central considerations, the market benefits from increasing physician confidence in supervised medical use supported by laboratory diagnostics and standardized care pathways.
Rising Prevalence of Testosterone Deficiency and Hormonal Disorders
Testosterone deficiency, also called hypogonadism, is becoming more common worldwide. This condition may be caused by aging, obesity, diabetes, genetic disorders, or injury to the testes. Symptoms include fatigue, low libido, depression, reduced muscle mass, and infertility.
As healthcare systems improve screening and diagnosis, more men are being identified with low testosterone levels. Early testing and better awareness among physicians have increased prescription rates of androgen therapies. This steady rise in diagnosed cases directly supports market growth.
Shift Toward Personalized Hormone Optimization
Clinics increasingly adopt individualized dosing strategies based on comprehensive hormone profiling and metabolic assessment. Regular laboratory reviews allow physicians to fine-tune regimens according to patient response and tolerability. Personalized treatment models enhance patient satisfaction while ensuring adherence to safe therapeutic thresholds. The market reflects growing demand for customized endocrine management programs supported by digital dashboards and structured follow-up visits.
Integration of Digital Health Platforms
Digital monitoring tools, mobile applications, and secure patient portals enable real-time communication between physicians and patients. Telehealth consultations support therapy continuity while reducing logistical burdens. Electronic prescription systems streamline refills within regulated frameworks. Data-driven monitoring improves compliance and transparency, reinforcing responsible distribution practices across the Androgens and Anabolic Steroids Market.
Androgens and Anabolic Steroids Market Segmentation Analysis
By Indication
Hypogonadism represents the dominant indication due to rising diagnosis rates and established treatment guidelines. Anaemia and selected breast cancer applications contribute additional therapeutic demand under controlled protocols. Other indications include delayed puberty and chronic illness–related muscle wasting. Evidence-based treatment pathways expand adoption across hospitals and specialty clinics.
By Drugs
Testosterone remains the primary therapy due to broad clinical validation and availability in multiple formulations. Methyltestosterone and oxymetholone serve targeted therapeutic roles. Manufacturers continue refining delivery formats and controlled-release technologies to enhance differentiation and compliance.
By Type
Prescription drugs dominate market share due to strict regulatory control and required physician oversight. OTC products represent a limited segment where legal frameworks permit mild formulations. Strong governance ensures quality and safety standards across dispensing channels.
Androgens and Anabolic Steroids Market Regional Outlook
North America holds the largest share due to strong diagnostic penetration, established hormone therapy networks, and consistent prescription oversight. The United States leads adoption with advanced endocrine infrastructure and structured monitoring systems. Canada demonstrates steady growth supported by reimbursement pathways and specialist clinics.
Europe represents the second-largest market, driven by aging populations and tightly regulated hormone therapy practices across Germany, the United Kingdom, France, and Italy. Regulatory enforcement strengthens physician confidence and patient safety.
Competitive Landscape
The Androgens and Anabolic Steroids Market features multinational pharmaceutical companies, specialty hormone therapy providers, and compounding pharmacies operating within strict compliance frameworks.
- AbbVie Inc.,
- Pfizer Inc.,
- Teva Pharmaceuticals,
- Endo Pharmaceuticals Inc.,
- Bayer AG,
- GlaxoSmithKline (GSK),
- Cipla Limited,
- Sun Pharmaceutical Industries Ltd.,
- Hikma Pharmaceuticals,
- Antares Pharma Inc.,
- Amneal Pharmaceuticals,
- Clarus Therapeutics,
- Viatris Inc.,
- Aurobindo Pharma,
- Zydus Cadila
Companies prioritize long-acting injectables, transdermal systems, and enhanced bioavailability technologies to maintain competitive differentiation.
ATTRIBUTE DETAILS
| ATTRIBUTE | DETAILS |
| Research Period | 2020–2032 |
| Base Year | 2024 |
| Forecast Period | 2025–2032 |
| Historical Year | 2020–2023 |
| Unit | USD Million |
| By Indication (2020–2032; USD Million) | Hypogonadism; Anaemia; Breast Cancer; Others |
| By Drugs (2020–2032; USD Million) | Testosterone; Methyltestosterone; Oxymetholone; Others |
| By Type (2020–2032; USD Million) | Prescription Drugs; Over-the-Counter (OTC) Drugs |
| By Route of Administration (2020–2032; USD Million) | Oral; Parenteral; Others |
| By End-Users (2020–2032; USD Million) | Hospitals; Specialty Clinics; Homecare; Others |
| By Distribution Channel (2020–2032; USD Million) | Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Others |
| By Geography (2020–2032; USD Million) | North America (U.S., Canada, Mexico); Europe (Germany, France, U.K., Italy, Spain, Rest of Europe); Asia Pacific (China, Japan, India, South Korea, South-east Asia, Rest of Asia Pacific); Latin America (Brazil, Argentina, Rest of Latin America); Middle East & Africa (GCC Countries, South Africa, Rest of the Middle East and Africa) |
Browse Complete Report – https://www.credenceresearch.com/report/androgens-and-anabolic-steroids-market
About Us
Credence Research is a leading international provider of market intelligence and a key component in the due diligence process. We deliver high-quality, extensive, deep-dive reports that empower leaders and investors to make informed decisions and mitigate risks. Our strategic insights, based on extensive research frameworks and advanced data modeling, provide authoritative primary sources for evaluating market performance and potential across a wide range of industries.
To find out more, visit www.credenceresearch.com or follow us on X.com, LinkedIn andFacebook.
Contact Us –
Credence Research Inc,
Tower C-1105, S 25,
Akash Tower,
Vishal Nagar,
Pimple Nilakh, Haveli,
Pune – 411027, India
USA: +1-888-600-6441
Email: sales@credenceresearch.com
Visit Our Website: https://www.credenceresearch.com/
